Equity Overview
Price & Market Data
Price: $7.25
Daily Change: $0.00 / 0.00%
Range: $7.25 - $7.25
Market Cap: $927,949,248
Volume: 100
Performance Metrics
1 Week: -7.06%
1 Month: -0.58%
3 Months: -12.10%
6 Months: -24.22%
1 Year: -46.13%
YTD: -12.10%
Details
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Camberwell, Australia.